The capital infusion is earmarked for a broad array of corporate objectives, including product development, strategic partnerships, and the acquisition of new intellectual property. Scilex, which specializes in treatments for acute and chronic pain alongside neurodegenerative and cardiometabolic diseases, intends to use the funds to scale its internal operations and market reach. The transaction remains subject to customary closing conditions before it can be finalized.
In section Market Quotes
Scilex Secures $100 Million Injection from Kazakhstan-Based iHolding
A private investment group, the Kazakhstan-based iHolding, has signed a binding term sheet to purchase $100 million in newly issued Scilex Holding shares. The deal, priced at $15.00 per share, involves the acquisition of approximately 6.7 million shares to bolster the company's expansion into non-opioid pain management and medical technology.
Comments (0)
No comments yet. Be the first!